Study to evaluate the safety, tolerability and antiretroviral activity of a new therapeutic strategy, based on the administration of dasatinib, an ITK, in patients with recent (3-12 months) asymptomatic HIV-1 infection.

Inclusion Criteria:

• 18 to 65 years.
• Documented asymptomatic HIV-1 infection of more than 3 months' duration (all patients must have a positive Western blot, including the p31 band whose appearance indicates infection of more than 90 days duration).
• Not having received ART
• CD4 T-lymphocyte count> 350 / μl
• Patient giving written informed consent

Exclusion Criteria:

• Active HBV (HBsAg+ or DNA+) and/or HCV (RNA+) infection in screening.
• ALT> 2 UNL, glomerular filtration rate <70 mL / 1.73 m2, leukocytes <4000 / mm3, total lymphocyte count <1000 / mm3, platelets <100,000 / mm3 or Hg <12g / dL.
• Pregnancy or active breastfeeding
• Ongoing or previous pleural effusion
• Chronic obstructive pulmonary disease, bronchial asthma or recent chest trauma.
• History of gastrointestinal or other bleeding.
• Any concomitant treatment with potentially dangerous drug interaction with dasatinib.
• Any clinical condition, at the opinion of the investigator, contraindicating participation (for example,
• Active neoplastic disease, active concomitant infection, etc.)